Equivalent results were shown in the NSCLC lung adenocarcinoma cell line, where knocking out CXCR2 or blocking with a small molecule antagonist decreased invasion and metastasis of cells expressing CXCR2. This evidence concerns the gene CXCR2 and non-small cell lung carcinoma.